Cancer immunotherapies targeting the PD-1 signaling pathway

• Iwai, Yoshiko

• Hamanishi, Junzo

• Chamoto, Kenji

• Honjo, Tasuku

Bibliographic Information

Other Title

• Cancer immunotherapies targeting the PD‐1 signaling pathway

Abstract

Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.

Journal

• Journal of Biomedical Science

  Journal of Biomedical Science 24 26-, 2017-04-04

  Springer Nature

Keywords

• PD-1
• PD-L1
• Cancer immunotherapy
• Immune checkpoint

Details

• CRID: 1050282810825874304
• NII Article ID: 120006309287
• ISSN: 14230127
• DOI: 10.1186/s12929-017-0329-9
• HANDLE: 2433/225265
• Web Site: http://link.springer.com/content/pdf/10.1186/s12929-017-0329-9.pdf
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN